Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BiondVax Pharmaceuticals has successfully passed a 2 day QP GMP audit during which the company`s manufacturing facility, production process, personnel and quality control procedures were examined in totality.
Subscribe to our email newsletter
The 2 day QP GMP passing facilitates the company to advance clinical development of its universal flu vaccine, M-001, in the EU.
BiondVax will also collaborate with MonoSol to investigate the activity of its influenza vaccine, M-001, when formulated using MonoSol PharmaFilm technology to be administered by mouth.
BiondVax CEO Ron Babecoff said the universality and immunogenicity of influenza vaccine, M-001, has been demonstrated in animal models and in the clinic.
”Now our success in passing the QP GMP audit demonstrates the professional nature of our facility, M-001 production process and team,” Babecoff added.